Phathom CEO’s $10.30 Share Buy Signals Belief in Undervalued Gut‑Therapeutic Pioneer Amid Market Doubts
Insider buy by Phathom owner Parikh Asit at $10.30 shows confidence that the drug‑maker is undervalued, but the trade is small and lacks market buzz, so investors should watch for new clinical or partnership data before betting on a rebound.
3 minutes to read